Key points are not available for this paper at this time.
BACKGROUND: amplification, may be biologically important to the actions of DDLPS. PATIENTS AND METHODS: 's utility as a clinical biomarker. in vitro and in vivo assessments were conducted in DDLPS cell lines. RESULTS: levels, and doxorubicin treatment elevated MDM2 expression. In vivo, treatment with doxorubicin followed by an MDM2 inhibitor improved doxorubicin sensitivity. CONCLUSION: as a predictive biomarker in DDLPS is warranted. IMPLICATIONS FOR PRACTICE: amplification may be a useful biomarker in DDLPS.
Bill et al. (Wed,) studied this question.